The Global Needle Free Injectors Market is projected to grow from USD 1,478.9 Million in 2024 to USD 2,980.9 Million by 2033, ...

On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...

The global needle-free vaccine injector market is projected to grow significantly, with estimated sales valued at USD 1,844.6 ...

I was in a private room and a pharmacist checked my health and if I had any allergies and then asked me to confirm some ...

On a basic level, companies able to offer an alternative form of vaccine delivery to traditional options can set themselves apart from competitors. Needle phobia is a well-known problem ...

Gentle nasal spray vaccines against COVID, the flu and RSV are coming. They may work better than shots in the arm ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

One such alternative is needle-free vaccines and studies have focused on the immune response few have addressed the welfare implications. This study aims to compare the impact of intradermal ...

World Vaccine Congress – Europe 2024 presentation, Improving Performance of Vaccines with Needle-free Technology will highlight the results of recent studies using needle-free delivery across ...

PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free ...